Analysts See $-0.09 EPS for Sophiris Bio, Inc. (SPHS); 0 Analysts Covering Consolidated Edison, Inc. (ED)

Sophiris Bio, Inc. (NASDAQ:SPHS) Logo

Among 6 analysts covering Consolidated Edison (NYSE:ED), 0 have Buy rating, 3 Sell and 3 Hold. Therefore 0 are positive. Consolidated Edison had 15 analyst reports since February 12, 2019 according to SRatingsIntel. As per Wednesday, February 13, the company rating was downgraded by Evercore. Barclays Capital maintained the stock with “Hold” rating in Wednesday, March 20 report. On Wednesday, March 13 the stock rating was maintained by Morgan Stanley with “Sell”. The rating was initiated by Mizuho on Monday, March 11 with “Hold”. UBS maintained it with “Hold” rating and $87 target in Friday, February 22 report. As per Tuesday, February 12, the company rating was maintained by Morgan Stanley. The rating was maintained by Credit Suisse on Monday, February 25 with “Underperform”. See Consolidated Edison, Inc. (NYSE:ED) latest ratings:

14/06/2019 Broker: Inc. Common Stock Rating: Morgan Stanley New Target: $87.0000 91.0000
05/06/2019 Broker: BidaskScore Rating: Hold Downgrade
16/05/2019 Broker: Inc. Common Stock Rating: Morgan Stanley New Target: $86.0000 87.0000
07/05/2019 Broker: BidaskScore Rating: Hold Upgrade
26/04/2019 Broker: Inc. Common Stock Rating: Bank Of America
02/04/2019 Broker: BidaskScore Rating: Hold Downgrade
20/03/2019 Broker: Barclays Capital Rating: Hold New Target: $85 Maintain
19/03/2019 Broker: BidaskScore Rating: Buy Downgrade
13/03/2019 Broker: Morgan Stanley Rating: Sell New Target: $83 Maintain
11/03/2019 Broker: Mizuho Rating: Hold New Target: $85 Initiate

Analysts expect Sophiris Bio, Inc. (NASDAQ:SPHS) to report $-0.09 EPS on August, 13.They anticipate $0.06 EPS change or 40.00% from last quarter’s $-0.15 EPS. After having $-0.08 EPS previously, Sophiris Bio, Inc.’s analysts see 12.50% EPS growth. The stock increased 1.01% or $0.01 during the last trading session, reaching $1. About 15,842 shares traded. Sophiris Bio, Inc. (NASDAQ:SPHS) has declined 65.26% since August 1, 2018 and is downtrending. It has underperformed by 65.26% the S&P500. Some Historical SPHS News: 14/05/2018 - Sophiris Bio 1Q Loss/Shr 11c; 21/03/2018 - SOPHIRIS - EXPECTS CASH & CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS TO MIDDLE OF 2019, ASSUMING NO NEW CLINICAL TRIALS; 21/03/2018 Sophiris Bio 4Q Loss/Shr 13c; 14/05/2018 - SOPHIRIS BIO INC - AT MARCH 31, 2018, CO HAD CASH, CASH EQUIVALENTS AND SECURITIES AVAILABLE-FOR-SALE OF $22.1 MLN AND WORKING CAPITAL OF $19.2 MLN; 14/05/2018 - SOPHIRIS BIO - EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPS TO MIDDLE OF 2019, ASSUMING NO NEW CLINICAL TRIALS ARE INITIATED; 22/04/2018 - DJ Sophiris Bio Inc, Inst Holders, 1Q 2018 (SPHS)

Investors sentiment increased to 1.31 in 2019 Q1. Its up 0.03, from 1.28 in 2018Q4. It increased, as 37 investors sold Consolidated Edison, Inc. shares while 196 reduced holdings. 88 funds opened positions while 217 raised stakes. 185.66 million shares or 1.06% less from 187.65 million shares in 2018Q4 were reported. Btim holds 0.66% or 575,826 shares in its portfolio. Massmutual Comm Fsb Adv invested in 0% or 75 shares. Blackrock Inc accumulated 29.17 million shares or 0.11% of the stock. Twin Cap Management Incorporated has 0.08% invested in Consolidated Edison, Inc. (NYSE:ED) for 19,120 shares. Clear Harbor Asset Ltd Llc holds 0.2% of its portfolio in Consolidated Edison, Inc. (NYSE:ED) for 11,720 shares. State Treasurer State Of Michigan holds 92,528 shares. Robeco Institutional Asset Mgmt Bv reported 1.48 million shares. Fund Mgmt, France-based fund reported 28,879 shares. Ferguson Wellman Mngmt holds 0.01% of its portfolio in Consolidated Edison, Inc. (NYSE:ED) for 3,751 shares. Court Place Ltd Liability Corporation accumulated 3,514 shares. 29,556 are owned by Old Bancshares In. Numerixs Investment Technologies Incorporated reported 0.11% in Consolidated Edison, Inc. (NYSE:ED). Associated Banc accumulated 11,445 shares or 0.06% of the stock. Pnc Fincl Service Grp holds 0.04% of its portfolio in Consolidated Edison, Inc. (NYSE:ED) for 484,242 shares. 2,472 are held by Co Of Toledo Na Oh.

More notable recent Consolidated Edison, Inc. (NYSE:ED) news were published by: Fool.com which released: “This High-Yield Dividend Stock Just Keeps Getting Better - Motley Fool” on July 30, 2019, also Finance.Yahoo.com with their article: “This High-Yield Stock Could Have Big News This Week - Yahoo Finance” published on July 29, 2019, Seekingalpha.com published: “Consolidated Edison Q2 2019 Earnings Preview - Seeking Alpha” on July 31, 2019. More interesting news about Consolidated Edison, Inc. (NYSE:ED) were released by: Seekingalpha.com and their article: “SPHD: The Ultimate ‘No Worries’ Income Plus Growth Investment - Seeking Alpha” published on July 30, 2019 as well as Globenewswire.com‘s news article titled: “Con Edison to Report 2nd Quarter 2019 Earnings on August 1 - GlobeNewswire” with publication date: July 16, 2019.

The stock increased 0.81% or $0.69 during the last trading session, reaching $85.65. About 207,956 shares traded. Consolidated Edison, Inc. (NYSE:ED) has risen 8.70% since August 1, 2018 and is uptrending. It has outperformed by 8.70% the S&P500. Some Historical ED News: 24/04/2018 - CONSOLIDATED EDISON INC - CON EDISON IS NOT ASSOCIATED WITH TRC CAPITAL, ITS MINI-TENDER OFFER OR MINI-TENDER OFFER DOCUMENTATION; 03/05/2018 - CONSOLIDATED EDISON INC - QTRLY ADJ SHR $1.38; 24/04/2018 - CONSOLIDATED EDISON, RECOMMENDS HOLDER REJECTION OF MINI-TENDER; 03/05/2018 - CONSOLIDATED EDISON INC ED.N REAFFIRMS FY 2018 ADJUSTED SHR VIEW $4.15 TO $4.35; 24/04/2018 - Consolidated Edison, Inc. Recommends Shareholder Rejection of Mini-Tender Offer by TRC Capital Corp; 23/04/2018 - CONSOLIDATED EDISON INC ED.N : UBS RAISES TARGET PRICE TO $79 FROM $77; 03/05/2018 - Consolidated Edison 1Q EPS $1.37; 13/03/2018 Retired President of Consolidated Edison Company of New York Elected to Ameren Board of Directors; 03/05/2018 - CONSOLIDATED EDISON INC - QTRLY SHR $1.38; 07/05/2018 - S&PGR Rts Consolidated Edison Co Of NY’s Sr Unsec Dbntrs ‘A-‘

Since January 31, 2019, it had 41 buys, and 0 insider sales for $140,083 activity. Another trade for 30 shares valued at $2,283 was bought by Cawley Timothy. $533 worth of Consolidated Edison, Inc. (NYSE:ED) was bought by OATES JOSEPH P on Thursday, January 31. $2,283 worth of Consolidated Edison, Inc. (NYSE:ED) was bought by HOGLUND ROBERT N on Thursday, January 31. Another trade for 49 shares valued at $4,334 was bought by Shukla Saumil P. McAvoy John bought 30 shares worth $2,283. de la Bastide Lore had bought 9 shares worth $796 on Sunday, June 30. Sanchez Robert also bought $4,334 worth of Consolidated Edison, Inc. (NYSE:ED) on Sunday, June 30.

Consolidated Edison, Inc., through its subsidiaries, engages in regulated electric, gas, and steam delivery businesses in the United States. The company has market cap of $28.02 billion. The firm offers electric services to approximately 3.4 million clients in New York City and Westchester County; gas to approximately 1.1 million clients in Manhattan, the Bronx, parts of Queens, and Westchester County; and steam to approximately 1,649 clients in parts of Manhattan. It has a 19.61 P/E ratio. It also supplies electricity to approximately 0.3 million clients in southeastern New York, and northern New Jersey; and gas to approximately 0.1 million clients in southeastern New York.

Among 3 analysts covering Sophiris Bio (NASDAQ:SPHS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio had 9 analyst reports since March 11, 2019 according to SRatingsIntel. The firm has “Buy” rating by Piper Jaffray given on Thursday, March 14. Maxim Group maintained the shares of SPHS in report on Thursday, March 14 with “Buy” rating. On Wednesday, June 19 the stock rating was maintained by Maxim Group with “Buy”. The rating was maintained by H.C. Wainwright on Thursday, March 14 with “Buy”.

Investors sentiment decreased to 0.44 in 2019 Q1. Its down 0.56, from 1 in 2018Q4. It is negative, as 2 investors sold Sophiris Bio, Inc. shares while 7 reduced holdings. 2 funds opened positions while 2 raised stakes. 2.48 million shares or 3.17% less from 2.56 million shares in 2018Q4 were reported. Bankshares Of Mellon Corporation has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Bancorp Of Montreal Can stated it has 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Hikari Power Ltd has 200,900 shares for 0.02% of their portfolio. Geode Mgmt Limited Liability Corp invested in 0% or 243,523 shares. Morgan Stanley stated it has 5,000 shares or 0% of all its holdings. Budros Ruhlin Roe Inc holds 40,000 shares. Virtu Ltd Com accumulated 24,234 shares or 0% of the stock. Citadel Limited Liability Company, a Illinois-based fund reported 16,080 shares. 34,328 are owned by B And T Dba Alpha. Vanguard Grp reported 1.39M shares. Sabby Mgmt Limited Liability Corporation reported 0.02% stake. Royal Bancshares Of Canada has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Blackrock, New York-based fund reported 72,220 shares. Moreover, Gp One Trading Lp has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 13,580 shares. Natl Bank Of America De invested 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS).

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $30.22 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

Consolidated Edison, Inc. (NYSE:ED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.